Pharma Leaders Rate Ability to Act on Diagnostic Insights Just 5.2/10, Diaceutics Survey Finds

Press Release
16 November 2026

Research among 125 senior US pharma leaders reveals a disconnect between commercialization priorities and capabilities, prompting calls for a more coordinated approach to getting eligible patients onto appropriate therapy.

Newport, New Jersey, 16 November 2026 – Pharmaceutical companies are struggling to translate diagnostic intelligence into coordinated action that helps eligible patients reach appropriate treatment, according to new research from intelligence and engagement company, Diaceutics.

The survey of 125 US pharma leaders, 85% of whom hold Director-level positions or above, found that respondents increasingly recognize the importance of converting diagnosis into treatment, rating its significance to future commercial success at an average of 7.5 out of 10. More than half (56.8%) strongly agreed that diagnosis-to-treatment conversion is now as important as traditional brand promotion. Yet respondents rated their organizations' effectiveness at turning diagnostic insights into coordinated action at just 5.2 out of 10.

Other key findings included:

  • 48.8% of respondents rated identified patients not starting appropriate therapy as a significant challenge.

  • Respondents rated their confidence in identifying eligible patients at 6.6 out of 10.

  • Asked what prevents eligible patients receiving appropriate therapy, respondents identified access/reimbursement (51.2%), late testing (47.2%), failure to identify patients (44.8%) and test results not leading to treatment (36.8%).

  • Respondents rated their organizations' visibility across the patient journey, from testing through to treatment initiation, at just 5.4 out of 10.

Together, the findings highlight the complexity of commercializing diagnostic-driven therapies, where successful treatment depends not only on identifying eligible patients but also on timely testing, appropriate clinical decisions and access to therapy.

Ryan Keeling, CEO of Diaceutics, said:

"The pharmaceutical industry has invested billions in developing increasingly precise therapies and sophisticated commercial capabilities, yet we're still struggling to connect the two. The industry is getting better at generating intelligence, but not necessarily at turning that intelligence into action when it matters. That's the contradiction the industry needs to confront and the challenge Diaceutics exists to help solve."

Industry leaders call for a new approach to commercialization.

The survey findings informed Diaceutics' Precision for All Strategic Collaboration, a new initiative bringing together senior leaders from across the pharmaceutical industry to explore how to close the gap between scientific innovation and real-world patient impact.

An initial discussion involving representatives from several top 20 pharma organizations identified the need to integrate diagnostic planning much earlier in therapy development and commercialization, rather than addressing testing infrastructure and adoption challenges after launch.
Participants also called for greater industry collaboration to tackle shared challenges, including inconsistent testing practices, fragmented patient pathways and limited coordination between stakeholders. They highlighted the potential for AI and advanced analytics to help clinicians navigate increasingly complex diagnostic and treatment information, provided these technologies are supported by reliable data and integrated into clinical workflows.

A participant in the discussion, Andrew Witriol, Vice President, US Oncology Marketing, Bristol Myers Squibb, commented:

"We've made remarkable progress in precision medicine, particularly in oncology. But developing increasingly targeted therapies is only part of the equation. We also must identify the right patients, ensure the right testing happens at the right time and help translate innovation into clinical practice.

For me, that's where the next opportunity lies: not just advancing the science but improving how we translate that science into real-world impact. Data and AI can help us better understand where patients may be getting lost along the journey and where we can act differently—but ultimately, it takes collaboration across the healthcare ecosystem to close those gaps."

Through its ongoing Precision for All Strategic Collaboration, Diaceutics aims to bring more industry leaders together to identify practical solutions to shared challenges, including diagnostic readiness, coordination across the patient pathway and expanding access to diagnostic-driven therapies across a growing range of diseases.

About Diaceutics

Diaceutics' vision is Precision for All: a future where every eligible patient is identified, diagnosed, and receives the right therapy at the right time. For more than 20 years, Diaceutics has helped biopharma companies overcome the diagnostic and commercialization barriers that stand between scientific innovation and patient impact. Today, it combines diagnostic intelligence, expert insight, and targeted engagement to unlock the full potential of diagnostic-driven therapies—and more life for the patients they are designed to serve.
For more information, visit www.diaceutics.com.

Media contacts: 
Louise Reid, Senior Account Director, UP THERE, EVERYWHERE: louise@upthereeverywhere.com

Lynn Wallace, Strategist & Account Director, UP THERE, EVERYWHERE: lynn-w@upthereeverywhere.com

 

About Diaceutics

At Diaceutics, our mission is to redefine commercialization for diagnostic-driven therapies, so every eligible patient is found, diagnosed and receives the right therapy at the right time. 

Share:

Newsletter sign up

Sign up to our bi-weekly newsletter covering the latest insights to optimize commercialization of diagnostic driven therapies to help empower your decisions.

READY TO DO COMMERCIALIZATION DIFFERENTLY?

Every patient journey contains opportunities to improve testing, engagement, and adoption. We can help you find them so more people get the right therapy sooner.